Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

209 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High-dose mitoxantrone and cyclophosphamide without stem cell support in patients with high-risk and advanced breast carcinoma: a Phase II multicentric trial.
Pérez-Gracia JL, Colomer R, Esteban E, Barceló R, Benavides M, Puertas J, Arcediano A, Tornamira MV, Valentín V, Muñoz A, Cortés-Funes H, Hornedo J. Pérez-Gracia JL, et al. Among authors: colomer r. Cancer. 2001 Nov 15;92(10):2508-16. doi: 10.1002/1097-0142(20011115)92:10<2508::aid-cncr1601>3.0.co;2-#. Cancer. 2001. PMID: 11745183 Clinical Trial.
High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study.
Colomer R, Llombart-Cussac A, Lloveras B, Ramos M, Mayordomo JI, Fernández R, Tusquets I, Gil M, Barnadas A, Constenla M, Gilabert M, Alba E. Colomer R, et al. Cancer. 2007 Nov 15;110(10):2178-85. doi: 10.1002/cncr.23043. Cancer. 2007. PMID: 17926331 Free article.
Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial.
Del Barco S, Colomer R, Calvo L, Tusquets I, Adrover E, Sánchez P, Rifà J, De la Haba J, Virizuela JA. Del Barco S, et al. Among authors: colomer r. Breast Cancer Res Treat. 2009 Jul;116(2):351-8. doi: 10.1007/s10549-008-0218-8. Epub 2008 Oct 22. Breast Cancer Res Treat. 2009. PMID: 18941891 Clinical Trial.
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study.
Swain SM, Ewer MS, Viale G, Delaloge S, Ferrero JM, Verrill M, Colomer R, Vieira C, Werner TL, Douthwaite H, Bradley D, Waldron-Lynch M, Kiermaier A, Eng-Wong J, Dang C; BERENICE Study Group. Swain SM, et al. Among authors: colomer r. Ann Oncol. 2018 Mar 1;29(3):646-653. doi: 10.1093/annonc/mdx773. Ann Oncol. 2018. PMID: 29253081 Free PMC article. Clinical Trial.
Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition.
Quintela-Fandino M, Apala JV, Malon D, Mouron S, Hornedo J, Gonzalez-Cortijo L, Colomer R, Guerra J. Quintela-Fandino M, et al. Among authors: colomer r. Breast Cancer Res. 2019 May 24;21(1):69. doi: 10.1186/s13058-019-1152-x. Breast Cancer Res. 2019. PMID: 31126332 Free PMC article. Clinical Trial.
209 results